Risks for Anaphylaxis With Intravenous Iron Formulations
Authors: Chintan V. Dave, Gary M. Brittenham, Jeffrey L. Carson, Soko Setoguchi
Journal: Annals of Internal Medicine (2022)

LettersNovember 2022Risks for Anaphylaxis With Intravenous Iron FormulationsChintan V. Dave, PharmD, PhD, Gary M. Brittenham, MD, Jeffrey L. Carson, MD, Soko Setoguchi, MD, DrPHChintan V. Dave, PharmD, PhDCenter for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, and Department of Veterans Affairs New Jersey Health Care System, New Brunswick, Piscataway, and East Orange, New JerseySearch for more papers by this author, Gary M. Brittenham, MDDepartment of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New YorkSearch for more papers by this author, Jeffrey L. Carson, MDDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New JerseySearch for more papers by this author, Soko Setoguchi, MD, DrPHCenter for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Medicine, Rutgers Robert Wood Johnson Medical School, and Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick and Piscataway, New JerseySearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L22-0283 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE: We thank Dr. Al-Samkari and colleagues for their correspondence but respectfully disagree with their comments and overall characterization of our study.We used a validated claims-based algorithm to identify anaphylaxis that comprised 3 components: anaphylactic hospitalizations (positive predictive value [PPV], 77%); use of codes for anaphylactic shock accompanied by evidence of cardiopulmonary resuscitation, hypotension, or administration of epinephrine (PPV, 73%); and anaphylaxis with multiple encounter types on the same day, such as (for example, an anaphylaxis-related outpatient and emergency department visit) (PPV, 88%) (1). Our case definitions do not include any use of antihistamines or the use of ...Reference1. Walsh K, Andrade S, Cocoros N, et al. Sentinel assessment report: parenteral iron and anaphylactoid reactions. U.S. Food and Drug Administration. 22 July 2016. Accessed at www.sentinelinitiative.org/sites/default/files/surveillance-tools/routine-querying/Sentinel_Parenteral-Iron-and-Anaphylactoid-Reactions_Report.pdf on 26 September 2022. Google Scholar Author, Article, and Disclosure InformationAuthors: Chintan V. Dave, PharmD, PhD; Gary M. Brittenham, MD; Jeffrey L. Carson, MD; Soko Setoguchi, MD, DrPHAffiliations: Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, and Department of Veterans Affairs New Jersey Health Care System, New Brunswick, Piscataway, and East Orange, New JerseyDepartment of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, New YorkDepartment of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New JerseyCenter for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, Department of Medicine, Rutgers Robert Wood Johnson Medical School, and Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick and Piscataway, New JerseyDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-4009. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoRisks for Anaphylaxis With Intravenous Iron Formulations Chintan V. Dave , Gary M. Brittenham , Jeffrey L. Carson , and Soko Setoguchi Risks for Anaphylaxis With Intravenous Iron Formulations Hanny Al-Samkari , John A. Glaspy , Robert T. Means Jr. , Glenn M. Chertow , Michael Auerbach Metrics November 2022Volume 175, Issue 11Page: W143-W144KeywordsAdverse eventsAnaphylaxisConfidence intervalsDextranMedicarePenicillinPositive predictive valueRandomized trialsRelative riskSucrose ePublished: 15 November 2022 Issue Published: November 2022 Copyright & PermissionsCopyright © 2022 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...